Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04342572 · ClinicalTrials.gov registry record · Phase 1
Intra-arterial Chemotherapy for Retinoblastoma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04342572 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 5 participants.
The verdict
NCT04342572, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
Children with retinoblastoma who may benefit from intra-arterial chemotherapy will receive up to 3 doses of melphalan and will be assessed for feasibility, toxicity, and response.
Interventions
- DRUG Melphalan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-08-11 |
| Est. Completion | 2025-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04342572
The ClinicalTrials.gov registry entry for NCT04342572 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Melphalan is the first listed.
NCT04342572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04342572 about?
NCT04342572 is a clinical study titled "Intra-arterial Chemotherapy for Retinoblastoma". Children with retinoblastoma who may benefit from intra-arterial chemotherapy will receive up to 3 doses of melphalan and will be assessed for feasibility, toxicity, and response.
What is the current status of trial NCT04342572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-08-11. Estimated completion is 2025-03-21.
What interventions are being tested in trial NCT04342572?
The interventions under investigation include: Melphalan (DRUG).
Who is sponsoring clinical trial NCT04342572?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.